MEREO BIOPHARMA GROUP PLC Research and Development Expense
MEREO BIOPHARMA GROUP PLC (MREO) reported Research and Development Expense of $1.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC research and development expense for the quarter ending 2026-06-30 was $1.81M, a 66.35% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC research and development expense for the quarter ending 2026-03-31 was $4.75M, a 20.79% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC research and development expense for the quarter ending 2025-12-31 was $4.19M, a 52.47% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC research and development expense for the quarter ending 2025-09-30 was $4.27M, a 34.70% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC research and development expense for fiscal 2025 was $17.77M, a 15.12% decline from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC research and development expense for fiscal 2024 was $20.93M, a 20.16% increase from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC research and development expense for fiscal 2023 was $17.42M, a 40.89% decline from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC research and development expense for fiscal 2022 was $29.46M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.81M 10-Q · filed 2026-08-11 | $6.55M 10-Q · filed 2026-08-11 | $10.75M derived: sum of 3 quarters · filed 2026-08-11 | $15.02M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.75M 10-Q · filed 2026-05-12 | $8.94M derived: sum of 2 quarters · filed 2026-05-12 | $13.21M derived: sum of 3 quarters · filed 2026-05-12 | $18.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $8.46M derived: sum of 2 quarters · filed 2026-03-19 | $13.84M derived: sum of 3 quarters · filed 2026-08-11 | $17.77M 10-K · filed 2026-03-19 |
| 2025-09-30 | $4.27M 10-Q · filed 2025-11-10 | $9.64M derived: sum of 2 quarters · filed 2026-08-11 | $13.57M 10-Q · filed 2025-11-10 | $22.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $5.37M 10-Q · filed 2026-08-11 | $9.30M 10-Q · filed 2026-08-11 | $18.12M derived: sum of 3 quarters · filed 2026-08-11 | $21.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $3.93M 10-Q · filed 2026-05-12 | $12.75M derived: sum of 2 quarters · filed 2026-05-12 | $15.92M derived: sum of 3 quarters · filed 2026-05-12 | $20.87M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $8.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $11.99M derived: sum of 2 quarters · filed 2026-03-19 | $16.94M derived: sum of 3 quarters · filed 2026-03-19 | $20.93M 10-K · filed 2026-03-19 |
| 2024-09-30 | $3.17M 10-Q · filed 2025-11-10 | $8.12M derived: sum of 2 quarters · filed 2025-11-10 | $12.11M 10-Q · filed 2025-11-10 | $16.91M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $4.95M 10-Q · filed 2025-08-12 | $8.94M 10-Q · filed 2025-08-12 | $13.74M derived: sum of 3 quarters · filed 2025-08-12 | $17.34M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.99M 10-Q · filed 2025-05-13 | $8.80M derived: sum of 2 quarters · filed 2025-05-13 | $12.39M derived: sum of 3 quarters · filed 2025-05-13 | $16.10M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $8.40M derived: sum of 2 quarters · filed 2025-03-26 | $12.11M derived: sum of 3 quarters · filed 2025-03-26 | $17.42M 10-K · filed 2025-03-26 |
| 2023-09-30 | $3.59M 10-Q · filed 2024-11-12 | $7.31M derived: sum of 2 quarters · filed 2024-11-12 | $12.61M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $3.71M 10-Q · filed 2024-08-13 | $9.02M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $5.31M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $29.46M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |